Rapport Therapeutics, Inc. (RAPP) — SEC Filings
Rapport Therapeutics, Inc. (RAPP) — 28 SEC filings. Latest: 8-K (May 7, 2026). Includes 8 8-K, 6 SC 13G, 5 10-Q.
View Rapport Therapeutics, Inc. on SEC EDGAR
Overview
Rapport Therapeutics, Inc. (RAPP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Rapport Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $77.72 million, compared to $58.33 million for the same period in 2024. This 33.2% increase in net loss was primarily driven by a substantial rise in operating expenses, with
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 25 neutral, 1 mixed. The dominant filing sentiment for Rapport Therapeutics, Inc. is neutral.
Filing Type Overview
Rapport Therapeutics, Inc. (RAPP) has filed 1 4, 8 8-K, 5 10-Q, 1 DEF 14A, 1 10-K, 3 SC 13G/A, 6 SC 13G, 1 SC 13D, 1 S-1/A, 1 S-1 with the SEC between May 2024 to May 2026.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of RAPP's 14 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$77.72M |
| EPS | -$2.15 |
| Debt-to-Equity | 0.05 |
| Cash Position | $251.36M |
| Operating Margin | N/A |
| Total Assets | $535.32M |
| Total Debt | $23.71M |
Key Executives
- Dr. James I. Healy
- Dr. Maha Katabi
- Abraham N. Ceesay
- Abraham N. Ceesay, M.B.A.
Industry Context
Rapport Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on developing novel therapeutics for neurological disorders. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies in this space often rely on strategic partnerships and substantial capital raises to fund their pipelines through clinical trials and towards commercialization.
Top Tags
10-Q (3) · financials (3) · Biotechnology (2) · Net Loss (2) · sec-filing (2) · pharmaceutical (2) · biotech (2) · ipo (2) · Clinical Stage (1) · R&D Spending (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $77.72M | Increased from $58.33M in 2024 for the nine months ended September 30, 2025, representing a 33.2% increase. |
| Research and Development Expenses | $64.53M | Increased from $43.74M in 2024 for the nine months ended September 30, 2025, a 47.5% rise. |
| General and Administrative Expenses | $22.06M | Increased from $15.80M in 2024 for the nine months ended September 30, 2025, a 39.6% increase. |
| Cash and Cash Equivalents | $251.36M | Increased significantly from $56.81M at December 31, 2024, providing substantial liquidity. |
| Net Proceeds from Public Offering | $269.43M | Major capital infusion from an underwritten public offering of common stock during the nine months ended September 30, 2025. |
| Common Shares Outstanding | 47,661,138 | As of November 3, 2025, reflecting dilution from the public offering. |
| Total Assets | $535.32M | Increased from $314.93M at December 31, 2024, indicating growth in the company's financial base. |
| Net Loss (Q2 2025) | $48.2M | Increased from $35.6M in Q2 2024, reflecting higher operating expenses. |
| Net Loss (YTD Q2 2025) | $93.8M | Increased from $66.7M in YTD Q2 2024, indicating accelerated cash burn. |
| R&D Expenses (Q2 2025) | $40.0M | Up from $29.7M in Q2 2024, driven by RAP-219 and preclinical program advancement. |
| Cash & Equivalents (June 30, 2025) | $300.0M | Decreased from $360.0M at December 31, 2024, before subsequent financing. |
| Private Placement Proceeds (July 2025) | $150.0M | New capital infusion to extend cash runway and fund operations. |
| SEC File Number | 001-42121 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 88-0724208 | Company's tax identification number. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
Frequently Asked Questions
What are the latest SEC filings for Rapport Therapeutics, Inc. (RAPP)?
Rapport Therapeutics, Inc. has 28 recent SEC filings from May 2024 to May 2026, including 8 8-K, 6 SC 13G, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RAPP filings?
Across 28 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 25 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Rapport Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Rapport Therapeutics, Inc. (RAPP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Rapport Therapeutics, Inc.?
Key financial highlights from Rapport Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RAPP?
The investment thesis for RAPP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Rapport Therapeutics, Inc.?
Key executives identified across Rapport Therapeutics, Inc.'s filings include Dr. James I. Healy, Dr. Maha Katabi, Abraham N. Ceesay, Abraham N. Ceesay, M.B.A..
What are the main risk factors for Rapport Therapeutics, Inc. stock?
Of RAPP's 14 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Rapport Therapeutics, Inc.?
Forward guidance and predictions for Rapport Therapeutics, Inc. are extracted from SEC filings as they are enriched.